Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 4
1999 1
2000 3
2002 3
2003 4
2004 4
2005 1
2006 2
2007 2
2008 3
2009 6
2010 3
2011 3
2012 4
2013 2
2014 2
2015 2
2016 1
2017 1
2018 3
2019 2
2020 2
2021 7
2022 4
2023 2
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
Voissière A, Gomez-Roca C, Chabaud S, Rodriguez C, Nkodia A, Berthet J, Montane L, Bidaux AS, Treilleux I, Eberst L, Terret C, Korakis I, Garin G, Pérol D, Delord JP, Caux C, Dubois B, Ménétrier-Caux C, Bendriss-Vermare N, Cassier PA. Voissière A, et al. Among authors: terret c. Sci Transl Med. 2024 Jan 24;16(731):eadd1834. doi: 10.1126/scitranslmed.add1834. Epub 2024 Jan 24. Sci Transl Med. 2024. PMID: 38266104
CPT-11. The European experience.
Armand JP, Terret C, Couteau C, Rixe O. Armand JP, et al. Among authors: terret c. Ann N Y Acad Sci. 1996 Dec 13;803:282-91. doi: 10.1111/j.1749-6632.1996.tb26398.x. Ann N Y Acad Sci. 1996. PMID: 8993522 Review.
[What's new in geriatric oncology?].
Terret C, Albrand G, Jeanton M, Courpron P, Droz JP. Terret C, et al. Bull Cancer. 2006 Jan;93(1):119-23. Bull Cancer. 2006. PMID: 16455514 Free article. Review. French.
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
Gomez-Roca C, Cassier P, Zamarin D, Machiels JP, Perez Gracia JL, Stephen Hodi F, Taus A, Martinez Garcia M, Boni V, Eder JP, Hafez N, Sullivan R, Mcdermott D, Champiat S, Aspeslagh S, Terret C, Jegg AM, Jacob W, Cannarile MA, Ries C, Korski K, Michielin F, Christen R, Babitzki G, Watson C, Meneses-Lorente G, Weisser M, Rüttinger D, Delord JP, Marabelle A. Gomez-Roca C, et al. Among authors: terret c. J Immunother Cancer. 2022 May;10(5):e004076. doi: 10.1136/jitc-2021-004076. J Immunother Cancer. 2022. PMID: 35577503 Free PMC article. Clinical Trial.
Patients' selection and trial matching in early-phase oncology clinical trials.
Corbaux P, Bayle A, Besle S, Vinceneux A, Vanacker H, Ouali K, Hanvic B, Baldini C, Cassier PA, Terret C, Verlingue L. Corbaux P, et al. Among authors: terret c. Crit Rev Oncol Hematol. 2024 Apr;196:104307. doi: 10.1016/j.critrevonc.2024.104307. Epub 2024 Feb 23. Crit Rev Oncol Hematol. 2024. PMID: 38401694 Free article. Review.
[Metabolic homeostasis as the cornerstone of aging].
Terret C, Solari F. Terret C, et al. Med Sci (Paris). 2012 Mar;28(3):311-5. doi: 10.1051/medsci/2012283020. Epub 2012 Apr 6. Med Sci (Paris). 2012. PMID: 22480656 Free article. Review. French.
67 results